Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc

Key Points
Bought 18,686 shares; estimated trade size ~$8.70 million based on quarterly average price for Q3 2025
Transaction represents 0.2% of fund’s 13F reportable assets under management
Post-trade position: 104,361 shares valued at $50.62 million as of September 30, 2025
Now accounts for 1.19% of the fund’s U.S. equity holdings, outside its top five positions
Image source: Getty Images
On October 17, 2025, E. Ohman J:or Asset Management AB disclosed a buy of 18,686 shares of Thermo Fisher Scientific (NYSE:TMO), an estimated $8.70 million trade.
What happened
According to a filing with the Securities and Exchange Commission dated October 17, 2025, E. Ohman J:or Asset Management AB acquired 18,686 additional shares during Q3 2025. The estimated value of the trade, based on average closing prices during the quarter, was approximately $8.70 million. The fund reported holding 104,361 shares at quarter-end, with a total position value of $50.62 million.
What else to know
The transaction was a buy and now represents 1.19% of E. Ohman J:or Asset Management AB’s reportable U.S. equity assets as of September 30, 2025.
Top holdings after the filing:
MSFT: $396.72 million (9.3% of AUM) as of September 30, 2025
NVDA: $347.06 million (8.2% of AUM) as of September 30, 2025
GOOGL: $305.56 million (7.2% of AUM) as of September 30, 2025
AAPL: $262.11 million (6.2% of AUM) as of September 30, 2025
AMZN: $235.95 million (5.6% of AUM) as of September 30, 2025
As of October 16, 2025, shares were priced at $536.78, down 9.3% over the past year, underperforming the S&P 500 by 24.3 percentage points.
Reported trailing twelve months revenue of $43.21 billion and net income of $6.58 billion as of June 28, 2025.
The fund reported 398 total positions and $4.25 billion in U.S. equity assets as of its 13F filing.
Company Overview
Revenue (TTM)
$43.21 billion
Net Income (TTM)
$6.58 billion
Dividend Yield
0.31%
Price (as of market close October 16, 2025)
$536.78
Company Snapshot
Thermo Fisher Scientific operates at global scale, providing critical tools and services for scientific research, diagnostics, and drug development. The company leverages its diversified portfolio and broad customer base to drive consistent revenue growth.
Its product offerings include life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services across global markets.
Thermo Fisher Scientific generates revenue through the sale of reagents, instruments, consumables, diagnostics kits, and laboratory services, supported by direct sales, e-commerce, and third-party distribution channels.
The company serves pharmaceutical, biotechnology, clinical, academic, government, and industrial customers worldwide.
Foolish take
Thermo Fisher Scientific has seen its stock cool this year, but what looks like fatigue may instead be a reset for one of the market's most dependable compounders. Swedish fund E. Ohman J:or Asset Management increased its stake by nearly $9 million. This move reflects renewed conviction in the company that remains central in the life sciences industry.
Over the past year, Thermo Fisher's stock has eased after several strong years of growth. Investors have been cautious as biotech spending and lab equipment budgets soften, yet the company's fundamentals remain sound. Revenue stands above $43 billion over the past twelve months, and is supported by a portfolio that spans nearly every stage of drug development and diagnostics. Thermo Fisher's steady margins and pricing power give it the flexibility to reinvest in R&D and targeted acquisitions, thereby positioning itself to widen its moat in areas such as genetic testing and bioprocessing.
Markets can overlook the value of steady progress, and consistency is often what drives real compounding. For investors who are willing to look past the recent slowdown, Thermo Fisher still represents what disciplined growth looks like in practice, and its steady results make it a company worth holding through any market cycle.
Glossary
13F filing: A quarterly report by institutional investment managers disclosing their U.S. equity holdings to the SEC.
Assets under management (AUM): The total market value of investments managed on behalf of clients by a fund or firm.
Reportable assets: Investments that must be disclosed in regulatory filings, such as those required by the SEC.
Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.
Dividend yield: Annual dividends paid by a company divided by its current share price, shown as a percentage.
Biopharma services: Specialized services supporting pharmaceutical and biotechnology companies, including drug development and manufacturing.
Consumables: Products used up during laboratory or industrial processes, such as reagents or testing kits.
Direct sales: Selling products or services directly to customers without intermediaries.
Third-party distribution channels: Independent companies or agents that sell products on behalf of a manufacturer.
Quarter-end: The last day of a company’s fiscal quarter, used for reporting financial results.
Estimated trade size: The approximate dollar value of a securities transaction, often based on average prices.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,033%* — a market-crushing outperformance compared to 193% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Eric Trie has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Microsoft, Nvidia, and Thermo Fisher Scientific. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher’s Pullback Is Setting Up Its Next Phase of Growth

Last Friday, the three most widely followed benchmark indexes closed a winning week. The tech-heavy Nasdaq, the Dow Jones and the S&P 500 gained 2.3%, 2.2% and 1.9%, respectively.
The S&P 500 and Nasdaq registered their sharpest weekly advances since August, while the Dow Jones Industrial Average recorded its strongest weekly show since June.
The week’s trading reflects a mix of reduced trade-war fears between the United States and China, inflation coming in cooler than expected and U.S. sanctions on Russian oil firms shifting the energy market. The weaker-than-forecast inflation reading bolstered hopes for a rate cut by the Fed, lifting investor sentiment. Next week, markets will focus on upcoming central-bank commentary and big tech earnings.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Micron and Napco Security Surge Following Zacks Rank Upgrade
Shares of Micron Technology, Inc. MU have gained 77.3% (versus the S&P 500’s 5.3% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on August 19.
Another stock, Napco Security Technologies, Inc. NSSC, which was also upgraded to a Rank #1 on August 28, has returned 14.8% (versus the S&P 500’s 4.7% increase) since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +8.64% in 2025 (through September 1st) vs. +7.60% for the S&P 500 index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through September 1st, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.8% vs. +11.3% for the S&P 500 index).
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades PDD and Seacoast Banking
Shares of PDD Holdings Inc. PDD and Seacoast Banking Corporation of Florida SBCF have surged 9.6% (versus the S&P 500’s 4.4% rise) and 6.7% (versus the S&P 500’s 6.1% rise), respectively, since their Zacks Recommendation was upgraded to Outperform on August 29 and August 21.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Lam Research, Shopify Shoot Up
Shares of Lam Research Corporation LRCX, which belongs to the Zacks Focus List, have gained 56.4% over the past 12 weeks. The stock was added to the Focus List on December 5, 2016. Another Focus-List holding, Shopify Inc. SHOP, which was added to the portfolio on September 6, 2022, has returned 39% over the past 12 weeks. The S&P 500 has advanced 6.3% over this period.
The 50-stock Focus List portfolio returned 18.3% in 2025 (through September 30th, 2025) vs. +14.8% for the S&P 500 index and +9.9% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
The portfolio leads the broader market over the preceding one, three, five and ‘since 2004’ periods. These annualized return comparisons are: +16.96% for the Focus List vs. +17.60% for the index over the one-year period, +26.77% vs. +24.94% over the 3-year period, +17.38% vs. +14.48% over the 5-year period, and +12.13% vs. +10.71% since 2004.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Thermo Fisher & Fair Isaac Make Significant Gains
Thermo Fisher Scientific Inc. TMO, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 19.7% over the past 12 weeks. Fair Isaac Corporation FICO has followed Thermo Fisher with 8.8% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +0.20% in the second quarter of 2025 vs. the S&P 500 index’s +10.94% gain (SPY ETF). In the year-to-date period through June 30th, the portfolio returned +3.93% vs. +6.20% gain for the S&P 500 index.
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks UnitedHealth and 3M Outperform Peers
UnitedHealth Group Incorporated UNH, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 29% over the past 12 weeks. Another ECDP stock, 3M Company MMM, has climbed 11.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -3.17% in 2025 Q2 vs. the S&P 500 index’s +10.94% gain and the Dividend Aristocrats ETF’s (NOBL) -0.09% return. Year-to-date (through June 30th), the portfolio returned +2.38% vs. +2.18% gain for the Dividend Aristocrat ETF.
For the full year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock Credo Technology Delivers Solid Returns
Credo Technology Group Holding Ltd CRDO, from the Zacks Top 10 Stocks for 2025, has jumped 131.4% year to date compared with the S&P 500 Index’s 15.6% increase.
The Top 10 portfolio returned +26.47% this year (through the end of September 2025) vs. +14.84% for the S&P 500 index and +9.9% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +2,553.1% through the end of September 2025 vs. +545.2% for the S&P 500 index and +396.4% for the equal-weight version of the index. The portfolio has produced an average return of +26.6% in the period 2012 through September 30, 2025, vs. +13.1% for the S&P 500 index and +10.5% for the equal-weight version of the index.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Beat the Market the Zacks Way: PDD, Shopify, 3M in Focus

In recent trading, shares of Thermo Fisher Scientific Inc (Symbol: TMO) have crossed above the average analyst 12-month target price of $642.67, changing hands for $646.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 15 different analyst targets within the Zacks coverage universe contributing to that average for Thermo Fisher Scientific Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $525.00. And then on the other side of the spectrum one analyst has a target as high as $715.00. The standard deviation is $72.008.
But the whole reason to look at the average TMO price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with TMO crossing above that average target price of $642.67/share, investors in TMO have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $642.67 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Thermo Fisher Scientific Inc:
Recent TMO Analyst Ratings Breakdown
»
Current
1 Month Ago
2 Month Ago
3 Month Ago
Strong buy ratings:
14
15
15
16
Buy ratings:
1
1
0
0
Hold ratings:
1
1
1
1
Sell ratings:
0
0
0
0
Strong sell ratings:
0
0
0
0
Average rating:
1.16
1.15
1.13
1.12
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on TMO — FREE.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TMO Crosses Above Average Analyst Target

Fintel reports that on October 23, 2025, Wells Fargo maintained coverage of Thermo Fisher Scientific (NYSE:TMO) with a Overweight recommendation.
Analyst Price Forecast Suggests 0.99% Downside
As of September 30, 2025, the average one-year price target for Thermo Fisher Scientific is $566.27/share. The forecasts range from a low of $505.00 to a high of $805.35. The average price target represents a decrease of 0.99% from its latest reported closing price of $571.94 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Thermo Fisher Scientific is 48,792MM, an increase of 11.56%. The projected annual non-GAAP EPS is 28.08.
What is the Fund Sentiment?
There are 3,778 funds or institutions reporting positions in Thermo Fisher Scientific. This is an decrease of 12 owner(s) or 0.32% in the last quarter. Average portfolio weight of all funds dedicated to TMO is 0.51%, an increase of 12.69%. Total shares owned by institutions increased in the last three months by 0.79% to 387,653K shares. The put/call ratio of TMO is 0.70, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,136K shares representing 3.21% ownership of the company. In its prior filing, the firm reported owning 11,913K shares , representing an increase of 1.84%. The firm decreased its portfolio allocation in TMO by 25.94% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 10,716K shares representing 2.84% ownership of the company. In its prior filing, the firm reported owning 10,627K shares , representing an increase of 0.82%. The firm decreased its portfolio allocation in TMO by 27.01% over the last quarter.
Capital World Investors holds 9,579K shares representing 2.54% ownership of the company. In its prior filing, the firm reported owning 11,061K shares , representing a decrease of 15.48%. The firm decreased its portfolio allocation in TMO by 36.70% over the last quarter.
Jpmorgan Chase holds 9,154K shares representing 2.42% ownership of the company. In its prior filing, the firm reported owning 10,138K shares , representing a decrease of 10.75%. The firm decreased its portfolio allocation in TMO by 34.11% over the last quarter.
Geode Capital Management holds 8,115K shares representing 2.15% ownership of the company. In its prior filing, the firm reported owning 8,127K shares , representing a decrease of 0.15%. The firm decreased its portfolio allocation in TMO by 61.57% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Wells Fargo Maintains Thermo Fisher Scientific (TMO) Overweight Recommendation

Pre-market futures are flattish at this hour, but with a downward bias. The Dow is coming off a record closing high Tuesday, and Q3 earnings reports released yesterday afternoon did not quite have the positive sheen we’ve seen elsewhere this far into earnings season. The Dow is currently down -9 points, the S&P 500 is +3, the Nasdaq -38 and the small-cap Russell 2000 is -9 points at this hour.
Fed Governor Michael Barr will make a couple of appearances later today — one week ahead of the next monetary policy decision from the Federal Open Market Committee (FOMC). Thus, we’re also closing in on the “blackout period,” where Fed members keep mum on their opinions about the state of the economy. Nearly 100% of analysts believe another 25 basis-point (bps) rate cut is in the cards for next Wednesday, which would take the Fed funds rate down to 3.75-4.00%.
Q3 Earnings Ahead of the Bell: T, TMO, GEV & More
AT&T T reported Q3 earnings ahead of today’s open, missing on its bottom line by a penny to 54 cents per share. Revenues in the quarter were similarly short, -0.81% from estimates to $30.71 billion. Shares are down -1.6% at this hour on the news; the stock is still up +13% year to date — basically in-line with the S&P 500.
Medical equipment major Thermo Fisher TMO posted beats on both top and bottom lines for its Q3 report this morning, with earnings of $5.79 per share well ahead of the $5.50 in the Zacks consensus. This amounts to a positive earning surprise of +5.27%. Revenues topped expectations by +2% to $11.12 billion in the quarter. Shares are up +2% on the news this morning, but still underperforming the S&P year to date.
A day after GE Aerospace GE strongly outperformed estimates, its energy-oriented spinoff GE Vernova GEV came out with a mixed picture in Q3: earnings of $1.64 per share missed the Zacks consensus $1.78 by -7.87% (though much higher than the 35 cents per share reported a year ago), on revenues of $9.97 billion — +8.62% higher than anticipated. Shares are up another +3.8% on the news, adding to the boffo +78% growth year to date.
Canadian metals company Teck Resources TECK had perhaps the strongest Q3 earnings report of the morning, with earnings of 55 cents per share surpassing the 39 cents projected by +41%, on revenues of $2.46 billion which surged past the Zacks consensus by +14.3%. This is perhaps a less familiar stock to track, but with rare earth negotiations with China remaining a sticking point, Teck may find itself with a higher level of relevancy.
What to Expect from Today’s Stock Market
Big Q3 earnings reports are expected after the closing bell today, including Tesla TSLA, which is expected to fetch negative earnings per share to the tune of -26.4% year over year, but +5% on revenues. Shares have rebounded somewhat from their much-maligned levels in early April, which was right around the time CEO Elon Musk was seeing his White House tenure coming to an end. Shares are +9.6% year to date, but flat ahead of today’s open.
We’ll also get IBM IBM earnings after today’s close, with the international tech giant looking to add to its +28% gains since the start of the year. Earnings are expected to come in +6% higher, with +7.57% on the revenues side for the quarter. Also, Southwest Airlines LUV fights a tough year-over-year comp, staring down -93% earnings growth in the quarter on +1.44% expected in revenues.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Southwest Airlines Co. (LUV) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
Teck Resources Ltd (TECK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Futures Flat at This Hour

Wednesday, October 22, 2025
Pre-market futures are flattish at this hour, but with a downward bias. The Dow is coming off a record closing high Tuesday, and Q3 earnings reports released yesterday afternoon did not quite have the positive sheen we’ve seen elsewhere this far into earnings season. The Dow is currently down -9 points, the S&P 500 is +3, the Nasdaq -38 and the small-cap Russell 2000 is -9 points at this hour.
Fed Governor Michael Barr will make a couple of appearances later today — one week ahead of the next monetary policy decision from the Federal Open Market Committee (FOMC). Thus, we’re also closing in on the “blackout period,” where Fed members keep mum on their opinions about the state of the economy. Nearly 100% of analysts believe another 25 basis-point (bps) rate cut is in the cards for next Wednesday, which would take the Fed funds rate down to 3.75-4.00%.
Q3 Earnings Ahead of the Bell: T, TMO, GEV & More
AT&T T reported Q3 earnings ahead of today’s open, missing on its bottom line by a penny to 54 cents per share. Revenues in the quarter were similarly short, -0.81% from estimates to $30.71 billion. Shares are down -1.6% at this hour on the news; the stock is still up +13% year to date — basically in-line with the S&P 500. For more on T’s earnings, click here.
Medical equipment major Thermo Fisher TMO posted beats on both top and bottom lines for its Q3 report this morning, with earnings of $5.79 per share well ahead of the $5.50 in the Zacks consensus. This amounts to a positive earning surprise of +5.27%. Revenues topped expectations by +2% to $11.12 billion in the quarter. Shares are up +2% on the news this morning, but still underperforming the S&P year to date. For more on TMO’s earnings, click here.
A day after GE Aerospace GE strongly outperformed estimates, its energy-oriented spinoff GE Vernova GEV came out with a mixed picture in Q3: earnings of $1.64 per share missed the Zacks consensus $1.78 by -7.87% (though much higher than the 35 cents per share reported a year ago), on revenues of $9.97 billion — +8.62% higher than anticipated. Shares are up another +3.8% on the news, adding to the boffo +78% growth year to date. For more on GEV’s earnings, click here.
Canadian metals company Teck Resources TECK had perhaps the strongest Q3 earnings report of the morning, with earnings of 55 cents per share surpassing the 39 cents projected by +41%, on revenues of $2.46 billion which surged past the Zacks consensus by +14.3%. This is perhaps a less familiar stock to track, but with rare earth negotiations with China remaining a sticking point, Teck may find itself with a higher level of relevancy. For more on TECK’s earnings, click here.
What to Expect from Today’s Stock Market
Big Q3 earnings reports are expected after the closing bell today, including Tesla TSLA, which is expected to fetch negative earnings per share to the tune of -26.4% year over year, but +5% on revenues. Shares have rebounded somewhat from their much-maligned levels in early April, which was right around the time CEO Elon Musk was seeing his White House tenure coming to an end. Shares are +9.6% year to date, but flat ahead of today’s open.
We’ll also get IBM IBM earnings after today’s close, with the international tech giant looking to add to its +28% gains since the start of the year. Earnings are expected to come in +6% higher, with +7.57% on the revenues side for the quarter. Also, Southwest Airlines LUV fights a tough year-over-year comp, staring down -93% earnings growth in the quarter on +1.44% expected in revenues.
Questions or comments about this article and/or author? Click here>>
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AT&T Inc. (T) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Q3 Earnings Bonanza Pulls a Flat Pre-Market: T, TMO, TSLA, etc.

(RTTNews) - Thermo Fisher Scientific (TMO) announced earnings for third quarter that beat the Street estimates.
The company's earnings came in at $1.616 billion, or $4.27 per share. This compares with $1.630 billion, or $4.25 per share, last year.
Excluding items, Thermo Fisher Scientific reported adjusted earnings of $2.190 billion or $5.79 per share for the period.
Analysts on average had expected the company to earn $5.50 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 4.9% to $11.122 billion from $10.598 billion last year.
Thermo Fisher Scientific earnings at a glance (GAAP) :
-Earnings: $1.616 Bln. vs. $1.630 Bln. last year. -EPS: $4.27 vs. $4.25 last year. -Revenue: $11.122 Bln vs. $10.598 Bln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Q3 Profit Beats Estimates

(RTTNews) - Thermo Fisher Scientific (TMO) will host a conference call at 8:30 AM ET on October 22, 2025, to discuss Q3 25 earnings results.
To access the live webcast, log on to https://ir.thermofisher.com/investors
To listen to the call, dial (833) 470-1428 (US) or (404) 975-4839 (International), access code 761271.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Q3 25 Earnings Conference Call At 8:30 AM ET

(RTTNews) - With earnings season in full swing, investors are turning their attention to a quartet of healthcare and biotech names, BSX, MEDP, MOH, and TMO, set to report Q3 results on October 22. From device makers to CROs and diagnostics giants, these updates could offer fresh insight into sector momentum and 2025 guidance trends.
Medical devices maker Boston Scientific Corp. (BSX) is slated to release its Q3 financial results on Wednesday, October 22. Wall Street analysts currently estimate earnings of $0.71 per share, with revenue expected to reach about $4.97 billion for the quarter.
In the comparable period last year, the company reported a GAAP net income of $469 million, or $0.32 per share. On an adjusted basis, earnings per share came in at $0.63, with net sales totaling $4.209 billion.
For the third quarter of 2025
Boston Scientific anticipates net sales growth in the range of about 17% - 19% on a reported basis, compared to the same period in the prior year.
On an organic basis, which excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures with less than a full period of comparable results, the company expects growth of 12% - 14%.
The company also projects third-quarter earnings per share on a GAAP basis to be in the range of $0.44 - $0.46. Adjusted earnings per share, which exclude certain charges and credits, are estimated to fall between $0.70 and $0.72.
Looking ahead to full-year 2025
Boston Scientific expects reported net sales growth of about 18% to 19% compared to the prior year. Organic net sales growth is projected to be in the range of 14% to 15%, again excluding the impact of foreign currency fluctuations and partial-period M&A activity.
For the full year, the company estimates GAAP earnings per share to be between $1.89 and $1.93. Adjusted earnings per share, excluding specified charges and credits, are expected to range from $2.95 to $2.99. Thirty-two Wall Street analysts have a consensus earnings estimate of $2.98 per share on revenue of $19.88 billion for 2025.
Stock Movement
BSX closed Tuesday's trade at $99.90, down 0.63%, with trading volume of over 7.68 million shares versus an average volume of 8.56 million shares. The stock has been trading in the range of $80.64 - $109.50 for the past 52-week period.
Global clinical contract research organization Medpace Holdings Inc. (MEDP) is due to report its third quarter 2025 financial results after the market close on Wednesday, October 22.
Wall Street analysts expect the company to report earnings of $3.57 per share and revenue of $640.98 million for the quarter.
For the third quarter of 2024, the company reported GAAP net income of $96.4 million, or $3.01 per share, on revenue of $533.3 million.
FY25 Guidance
The company forecasts 2025 revenue in the range of $2.420 billion - $2.520 billion, representing growth of 14.7% - 19.5% over 2024 revenue of $2.109 billion. Additionally, the full-year 2025 EBITDA is expected to be in the range of $515 million to $545 million.
GAAP net income is forecasted to be in the range of $405.0 million - $428.0 million, or $13.76 - $14.53 per share. Analysts expect EPS of $14.36 and revenue of $2.46 billion for 2025.
Stock Movement
MEDP surged to a new 52-week high on Tuesday, reaching an intraday peak of $554.14 before settling at $545.64. Trading volume topped 519K shares, well above the 381K-share average.
Managed healthcare services provider Molina Healthcare Inc. (MOH) is slated to issue its Q3 financial results after the market closes on Wednesday, October 22, 2025. Wall Street analysts estimate EPS of $3.89 and revenue of $10.98 billion for the quarter.
For the three months ended September 30, 2024, the company reported GAAP net income of $326 million or $5.65 per share, adjusted net income of $347 million or $6.01 per share on total revenue of $10.3 billion.
2025 Guidance
Premium revenue guidance for the full year is unchanged and expected to be about $42 billion, an increase of about 9% from the full year 2024. Analysts look for revenue of $44.56 billion for 2025.
The company now expects its full-year 2025 GAAP earnings to be no less than $16.90 per share and adjusted earnings to be no less than $19.00 per share. Seventeen Wall Street analysts have a consensus earnings estimate of $18.62 per share.
The updated guidance, which is disproportionately attributed to Marketplace, reflects new information gained in the quarterly closing process and implications for medical cost trend assumptions for the second half of the year.
Stock Movement
MOH edged lower on Tuesday, slipping 0.35% to close at $196.80. The stock traded within an intraday range of $187.23 to $199.21. Volume came in at 1.4 million shares, slightly below the 1.48 million average.
Life sciences solutions provider Thermo Fisher Scientific Inc. (TMO) is scheduled to publish its Q3 financial results before the market opens on Wednesday, October 22. Analysts are looking for earnings of $5.50 per share and revenue of $10.91 billion for the quarter.
In the comparable prior year period, the company posted GAAP EPS of $4.25, adjusted EPS of $5.28 on revenue of $10.60 billion.
FY25 Outlook
The company now anticipates FY25 revenue in the range of $43.6 billion - $44.2 billion with adjusted earnings per share between $22.22 and $22.84, representing a $0.23 increase at the midpoint. Analysts estimate EPS of $22.50 on revenue of $43.94 billion for 2025.
Stock Movement
TMO closed at $557.99 on Tuesday, up 2.6% for the day. The stock traded between $553.74 and $568.39, continuing its recovery from the June low of $385.46. Volume surged to nearly 3.93 million shares, well above the 2.4 million average.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Biotech Earnings Watch: BSX, MEDP, MOH, TMO Set To Report Oct 22

The following companies are expected to report earnings prior to market open on 10/22/2025. Visit our Earnings Calendar for a full list of expected earnings releases.
Thermo Fisher Scientific Inc (TMO)is reporting for the quarter ending September 30, 2025. The medical instruments company's consensus earnings per share forecast from the 10 analysts that follow the stock is $5.50. This value represents a 4.17% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.68%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for TMO is 24.17 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry.
AT&T Inc. (T)is reporting for the quarter ending September 30, 2025. The wireless (national) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.55. This value represents a 8.33% decrease compared to the same quarter last year. T missed the consensus earnings per share in the 1st calendar quarter of 2025 by -1.92%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for T is 12.73 vs. an industry ratio of 5.40, implying that they will have a higher earnings growth than their competitors in the same industry.
GE Vernova Inc. (GEV)is reporting for the quarter ending September 30, 2025. The alternative energy company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.78. This value represents a 408.57% increase compared to the same quarter last year. GEV missed the consensus earnings per share in the 4th calendar quarter of 2024 by -25.43%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for GEV is 77.45 vs. an industry ratio of 145.00.
Amphenol Corporation (APH)is reporting for the quarter ending September 30, 2025. The electrical connectors company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.79. This value represents a 58.00% increase compared to the same quarter last year. In the past year APH has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 22.73%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for APH is 42.14 vs. an industry ratio of 42.20.
Boston Scientific Corporation (BSX)is reporting for the quarter ending September 30, 2025. The medical products company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.71. This value represents a 12.70% increase compared to the same quarter last year. In the past year BSX has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 4.17%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for BSX is 33.73 vs. an industry ratio of 7.90, implying that they will have a higher earnings growth than their competitors in the same industry.
CME Group Inc. (CME)is reporting for the quarter ending September 30, 2025. The securities exchange company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.63. This value represents a 1.87% decrease compared to the same quarter last year. In the past year CME has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 1.72%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for CME is 24.22 vs. an industry ratio of 23.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Moody's Corporation (MCO)is reporting for the quarter ending September 30, 2025. The financial services company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.70. This value represents a 15.26% increase compared to the same quarter last year. In the past year MCO has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.49%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for MCO is 33.67 vs. an industry ratio of 18.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Vertiv Holdings, LLC (VRT)is reporting for the quarter ending September 30, 2025. The information technology services company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.00. This value represents a 31.58% increase compared to the same quarter last year. In the past year VRT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 14.46%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for VRT is 45.76 vs. an industry ratio of 15.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Hilton Worldwide Holdings Inc. (HLT)is reporting for the quarter ending September 30, 2025. The hotel company's consensus earnings per share forecast from the 6 analysts that follow the stock is $2.04. This value represents a 6.25% increase compared to the same quarter last year. In the past year HLT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 7.84%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for HLT is 32.84 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Westinghouse Air Brake Technologies Corporation (WAB)is reporting for the quarter ending September 30, 2025. The transportation company's consensus earnings per share forecast from the 4 analysts that follow the stock is $2.27. This value represents a 13.50% increase compared to the same quarter last year. WAB missed the consensus earnings per share in the 4th calendar quarter of 2024 by -2.89%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for WAB is 22.04 vs. an industry ratio of 15.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Teledyne Technologies Incorporated (TDY)is reporting for the quarter ending September 30, 2025. The aerospace and defense company's consensus earnings per share forecast from the 5 analysts that follow the stock is $5.50. This value represents a 7.84% increase compared to the same quarter last year. In the past year TDY has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.59%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for TDY is 26.62 vs. an industry ratio of 56.90.
Northern Trust Corporation (NTRS)is reporting for the quarter ending September 30, 2025. The bank company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.26. This value represents a 15.31% increase compared to the same quarter last year. In the past year NTRS has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.4%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for NTRS is 14.93 vs. an industry ratio of 12.40, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Inc

Sign up and unlock all the capabilities of the AI-screener